Atrium Therapeutics presented new nonclinical data demonstrating that ATR 1072, their investigational RNA therapy, reversed key disease features in a mouse model of PRKAG2 syndrome, including cardiac glycogen accumulation and hypertrophy. PRKAG2 syndrome is a rare genetic heart condition with no approved treatments targeting its root cause. The company is currently conducting a Phase 1/2 clinical trial (Corventis) to evaluate ATR 1072's safety and efficacy, with initial human data expected in late 2027. These findings support ATR 1072 as a potential precision therapy for this rare cardiomyopathy.
Atrium Therapeutics' investigational RNA therapy ATR 1072 is highlighted as it shows promise in reversing features of PRKAG2 syndrome. For readers following the health sector, here is Pluang's market snapshot as of Nov 02, 2026 18:12 WIB: out of 150 priced US health stocks, 70 rose and 54 fell. Notable movers include HRTX at USD 0.29 with a 4.43% increase and a typical hold time of 38 days, ELAN at USD 22.18 down 3.82% with a 24-day hold, and XRAY at USD 9.89 up 3.78% with a 74-day hold.
Public Policy Holding Company, Inc. (PPHC) has acquired Reevemark LLC, a New York-based strategic communications firm specializing in litigation, crisis, and shareholder activism, for up to $80 million. This acquisition enhances PPHC's capabilities i...
New research by The Allstate Foundation of Canada shows that while 75% of Canadians have experienced or know someone who has experienced domestic abuse, only 9% recognize financial abuse as a form of it. However, 56% of abuse survivors identified fin...
Investec Bank plc, acting as joint broker for Pollen Street Group Limited, disclosed its share dealings on October 30, 2026. The bank purchased 4,503 ordinary shares and sold 1,946 ordinary shares at prices between 911 and 916 per unit. There were no...
Man Group PLC has publicly disclosed holding a 5.42% interest in Vesuvius plc's ordinary shares as of October 30, 2026. The disclosure includes details of cash-settled derivative transactions that slightly reduce their long position. This filing is p...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share dealings on October 30, 2026. The bank purchased 15,380 ordinary shares at a price of 282.75 per share and sold 201 shares at 283 each....
